Zyversa Therapeutics, Inc. ( (ZVSA) ) has released its Q2 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for chronic renal and inflammatory diseases using proprietary technologies. In its latest earnings report, ZyVersa highlighted a net loss of $4.5 million for the first half of 2025, a decrease from the $5.6 million loss in the same period of 2024. The company reported a cash balance of $72,086 as of June 30, 2025, and an accumulated deficit of $117.1 million, indicating ongoing financial challenges. Key financial metrics included operating expenses of $4.2 million and a working capital deficit of $12.1 million. The company also faced a significant event as its common stock was suspended from trading on Nasdaq and moved to the OTCQB Venture Market. Looking ahead, ZyVersa plans to continue developing its drug candidates and seeks additional financing to support its operations, acknowledging the challenges of achieving profitability in the near term.